340B Enters 2027 With New Economics and Greater Operational Complexity

Authors: Eve Jamali, MSc, SVP, Managing Director, Access Consulting; Madeline Waldron, PharmD, BCOP, SVP, Clinical Oncology Solutions

Two federal 340B changes are scheduled for January 1, 2027: a new Medicare reimbursement methodology for 340B-acquired drugs paid under OPPS and a new rebate model for selected drugs, subject to ongoing litigation. Together, they could affect working capital, service-line economics, site-of-care, patient support resources, and manufacturer account strategy.

Let's start with the changes at a high level:

*excluding rural sole community hospitals, PPS-exempt cancer hospitals and children's hospitals*

The OPPS Impact Will Vary by Product and Acquisition Channel

Beginning January 1, 2027, Medicare payment for 340B-acquired drugs paid under OPPS will move from ASP +6% to ASP -28%. The new rate reflects CMS’s assessment of 340B hospital acquisition costs following its 2026 hospital drug acquisition cost survey.

The financial impact will vary by product and acquisition channel. Payment follows whether the billed units were acquired through 340B and identified as such on the claim. It does not automatically apply to every unit associated with a J-code, or every drug claim submitted by a 340B hospital. CMS uses claim-line modifiers to identify drugs acquired through the 340B program.

The net economic impact will depend on each product's ASP, 340B acquisition price, applicable purchasing arrangements, and the acquisition status supported on the claim. A lower Medicare payment rate will not necessarily make 340B purchasing less favorable for every product.

CMS estimates that the policy will reduce Original Medicare drug payments by $4.35 billion and beneficiary payments by another $1.1 billion in 2027. Beneficiaries receiving qualifying drugs in hospital outpatient departments are expected to save approximately $900 on average.

The policy is budget neutral within OPPS, with lower payments for 340B-acquired drugs redistributed through higher payments for non-drug outpatient services. However, budget neutrality at the OPPS system level may not translate into neutrality for an individual hospital or service line. The reduction will be felt directly within drug reimbursement, while the offset is distributed across non-drug outpatient services and may not accrue to the same department or site of care. For pharmacy and specialty-care leaders managing a service-line P&L, the change may therefore be experienced as a direct reduction in contribution margin, even when the organization benefits from the broader OPPS increase.

This change also occurs alongside CMS’s separate 340B remedy recoupment, which reduces the 2027 OPPS conversion factor for applicable hospitals and may further complicate how organizations experience the overall payment update.

Selected Drugs May Move to a Rebate Model

The HRSA 340B Rebate Model Pilot is also scheduled for January 1, 2027, and currently includes selected drugs from 10 manufacturers. Instead of receiving the 340B price upfront, covered entities will generally purchase affected products at WAC and submit claims data for a rebate equal to the difference between WAC and the applicable 340B ceiling price.

The model introduces new working capital, claims submission, reconciliation, and denial-management requirements. It remains subject to litigation challenging implementation, including concerns about administrative costs and the capital required to purchase products at WAC before rebate receipt.

The pilot remains subject to litigation. The American Hospital Association, Maine Hospital Association and four safety-net hospitals are seeking to block implementation, citing administrative costs and the working capital required to purchase products at WAC before receiving rebates. As of November 5, 2026, the court had not ruled, and the pilot remained scheduled for January 1.

Impact Across the Market

1. Hospitals and Health Systems

Hospitals with significant Medicare 340B volume may experience lower pharmacy margins, although impact will vary by product, acquisition channel, and outpatient service mix. The rebate model adds a separate working-capital challenge by requiring covered entities to carry the difference between WAC and the eventual rebate.

Responses will also differ by provider type. Large IDNs may manage the impact across their outpatient portfolio and adjust purchasing, formulary, and site-of-care strategies. Safety-net and other covered entities more reliant on 340B economics may have less flexibility, potentially reassessing resources for navigation, financial counseling, patient assistance, pharmacy and infusion staffing, transportation, and other support services. Community practices may experience downstream changes in referrals and competitive dynamics as hospital systems reassess specialty-care delivery.

The change may also increase provider attention to the timing and economics of newly launched products. For eligible new drugs and biologicals, temporary OPPS pass-through status may receive temporary OPPS pass-through payment for at least two but no more than three years. In oncology and other specialty categories, this makes the timing of pass-through status, and the transition to standard OPPS payment after it expires, increasingly important as hospitals evaluate the economics of newly launched products. These considerations will vary based on clinical value, formulary approval, coding readiness, acquisition cost, 340B eligibility, and the product’s specific payment status.

For one product with IV and SC formulations, we changed our formulary decisions to have all new starts on SC to prepare for what will happen next year. The IV formulation for this drug and its competitors are now disadvantaged in EHR.

— Large 340b Hospital, VP Pharmacy

2. Clinics and Sites-of-Care

The ASP -28% policy applies to 340B-acquired drugs paid under OPPS. Independent physician offices operating outside OPPS are not directly subject to the same payment change.

Hospitals may reassess where high-cost physician-administered therapies are delivered. Depending on product economics, payer mix, referral control, and organizational structure, some systems may seek to retain treatment within 340B-eligible settings, while others may shift selected therapies toward affiliated or community sites where the reimbursement and acquisition-cost equation is more favorable. The direction of change will not be uniform, and moving care does not automatically preserve either 340B eligibility or the same economics. The result may be greater scrutiny of site-of-care economics, particularly for oncology and other specialty therapies with high drug costs and meaningful Medicare exposure.

3. Payers and Beneficiaries

Medicare will spend less on qualifying 340B-acquired drugs furnished in hospital outpatient departments. Beneficiaries will also pay less because their coinsurance is tied to the lower Medicare allowed amount.

Commercial reimbursement is not directly affected by the Medicare rule. However, the policy may add momentum to broader payer scrutiny of hospital outpatient drug costs and site-of-care differentials, particularly for high-cost physician-administered therapies. Plans may increasingly evaluate whether comparable care can be delivered in lower-cost settings, adding another variable to provider site-of-care decisions.

For the facilities, it will cut their margins. On commercial book of business, it's totally separate, but it may have some halo effect or be analogous to some of the MFP things that are going on, so seeing some of the indexing reimbursement scheme on the Medicare side flowing over the commercial because they look at the published MFP price on a drug, so now, commercial we look and realize the net isn't the same, and want to be closer to that net. We can’t get it all, but it helps us negotiate.

    — National Payer, Pharmacy Lead, P&T Committee

4. Manufacturers

For manufacturers of high-cost physician-administered therapies, a national policy change may ultimately require an account-level response. Two hospitals treating the same patient with the same product may experience materially different economics based on Medicare mix, 340B utilization, acquisition economics, and service mix. Account strategies that historically viewed "340B" as a single customer segment may therefore need greater segmentation by provider archetype and product-level economics.

For products included in the rebate pilot, manufacturers will also need claims validation, rebate payment, reconciliation, and dispute processes. The approved claims data offer greater transaction-level visibility into 340B utilization, subject to HRSA restrictions on how those data may be collected and used.

What Market Access Teams Should Watch

The market impact will not be uniform. Product economics may change materially at some 340B hospital accounts while remaining relatively stable at others. The most important questions will be:

• Which products and accounts face the greatest reduction in hospital drug margin?
• How much of the loss is recovered through higher non-drug OPPS payments?
• Could the change affect infusion location, referrals, or treatment pathways?
• Are claims, rebate, and reconciliation processes ready if the pilot proceeds?
• How should provider economics be reflected in forecasting and account strategy?
• Could reduced drug contribution margin constrain the navigation, financial assistance, staffing, and other support services that some covered entities sustain through 340B economics?

Learn More from Precision AQ’s Market Access Experts

To understand what evolving 340B policy could mean for your portfolio and market access strategy, contact our team.